Microbot Medical Inc (MBOT) Stock Analysis
Verdict: WATCH (do not buy)
LIBERTY commercial launch brings a $67.4M cash runway, but severe technical price degradation keeps risk elevated.
Investment score: 49/100
Analysis as of
Is Microbot Medical Inc stock worth reviewing? AI model thesis
Microbot Medical transitioned its LIBERTY system to full market release in April 2026, driving Q2 revenue up over 100% QoQ to $0.241M. With $67.37M in cash and short-term investments securing a 33-month runway, insolvency risk is low, but continuous technical downward pressure keeps the AI model on WATCH.
7-factor investment score
- Valuation: 58/100 (weight 20%)
- Financial Health: 62/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 52/100 (weight 15%)
Microbot Medical Inc opportunities and risks
What speaks for MBOT
- LIBERTY Full Market Release Acceleration
What speaks against MBOT
- Severe Technical Degradation and Momentum Weakness
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MBOT | n/a | 184.4x | n/a | -185.3% | -4722.3% | -28.1% |
| VANI | n/a | 0.0x | n/a | 0.0% | 0.0% | -26.2% |
| RTGN | n/a | 0.0x | 218.3x | 0.0% | 0.0% | -0.6% |
| OM | n/a | 0.6x | n/a | 41.8% | -63.1% | -52.6% |
| LNSR | 4.6x | 1.2x | 1.6x | 48.0% | 57.6% | -10.3% |
| ECOR | n/a | 1.9x | n/a | 87.1% | -40.0% | -13.8% |
| Peer median | n/a | 0.6x | n/a | 41.8% | 0.0% | -13.8% |
Frequently asked questions about Microbot Medical Inc (MBOT)
Is MBOT stock a good investment?
The cached TradeMates AI model rates Microbot Medical Inc as WATCH (do not buy) with an investment score of 49/100. Microbot Medical transitioned its LIBERTY system to full market release in April 2026, driving Q2 revenue up over 100% QoQ to $0.241M. With $67.37M in cash and short-term investments securing a 33-month runway, insolvency risk is low, but continuous technical downward pressure keeps the AI model on WATCH. This is algorithmic model output, not personal investment advice.
Is MBOT stock a buy?
The TradeMates model verdict for MBOT is WATCH (do not buy) with an investment score of 49/100. Treat this as a model signal to review, not a personal buy recommendation.